

Eric J Roeland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4155174/publications.pdf>

Version: 2024-02-01

179
papers

2,946
citations

236925

25
h-index

197818

49
g-index

183
all docs

183
docs citations

183
times ranked

4272
citing authors

#	ARTICLE	IF	CITATIONS
1	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	30.7	359
2	Management of Cancer Cachexia: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2438-2453.	1.6	292
3	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	7.0	178
4	Cancer Cachexia: Beyond Weight Loss. <i>Journal of Oncology Practice</i> , 2016, 12, 1163-1171.	2.5	162
5	NCCN Guidelines Insights: Antiemesis, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 883-893.	4.9	137
6	The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. <i>Annals of Oncology</i> , 2017, 28, 1260-1267.	1.2	134
7	Management of Dyspnea in Advanced Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 1389-1411.	1.6	74
8	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	7.0	67
9	Early Palliative Care for Patients with Hematologic Malignancies: Is It Really so Difficult to Achieve?. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 300-308.	2.3	66
10	When Open-Ended Questions Don't Work: The Role of Palliative Paternalism in Difficult Medical Decisions. <i>Journal of Palliative Medicine</i> , 2014, 17, 415-420.	1.1	65
11	Effect of Palliative Care on Aggressiveness of End-of-Life Care Among Patients With Advanced Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e760-e769.	2.5	61
12	A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 73.	17.0	57
13	Current concepts in malignant bowel obstruction management. <i>Current Oncology Reports</i> , 2009, 11, 298-303.	4.0	55
14	Predictors of Progression in High-Grade Appendiceal or Colorectal Peritoneal Carcinomatosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1716-1721.	1.5	54
15	Patterns of Palliative Care Consultation Among Elderly Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 439-445.	4.9	52
16	Feeling Heard and Understood: A Patient-Reported Quality Measure for the Inpatient Palliative Care Setting. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 150-154.	1.2	48
17	What do transplant physicians think about palliative care? A national survey study. <i>Cancer</i> , 2018, 124, 4556-4566.	4.1	47
18	Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 230, 912-924.	0.5	42

#	ARTICLE	IF	CITATIONS
19	Age Disparity in Palliative Radiation Therapy Among Patients With Advanced Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 224-230.	0.8	40
20	Concordance of Advance Care Plans With Inpatient Directives in the Electronic Medical Record for Older Patients Admitted From the Emergency Department. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 647-651.	1.2	39
21	Computed Tomography-based Body Composition Analysis and Its Role in Lung Cancer Care. <i>Journal of Thoracic Imaging</i> , 2020, 35, 91-100.	1.5	39
22	Palliative chemotherapy: oxymoron or misunderstanding?. <i>BMC Palliative Care</i> , 2016, 15, 33.	1.8	31
23	Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. <i>Supportive Care in Cancer</i> , 2017, 25, 365-369.	2.2	31
24	Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303. <i>Journal of Palliative Medicine</i> , 2020, 23, 922-929.	1.1	31
25	Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. <i>Annals of Oncology</i> , 2018, 29, 1535-1540.	1.2	27
26	A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. <i>Supportive Care in Cancer</i> , 2015, 23, 2231-2244.	2.2	25
27	Advance Care Planning and Palliative Care Integration for Patients Undergoing Hematopoietic Stem-Cell Transplantation. <i>Journal of Oncology Practice</i> , 2017, 13, e721-e728.	2.5	24
28	End-of-life care among adolescent and young adult patients with cancer living in poverty. <i>Cancer</i> , 2020, 126, 886-893.	4.1	24
29	Spanning the canyon between stem cell transplantation and palliative care. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 484-489.	2.5	21
30	Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. <i>Oncologist</i> , 2020, 25, e589-e597.	3.7	21
31	Barriers to Optimal End-of-Life Care for Adolescents and Young Adults With Cancer: Bereaved Caregiver Perspectives. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 528-533.	4.9	20
32	Operationalizing the Measuring What Matters Spirituality Quality Metric in a Population of Hospitalized, Critically Ill Patients and Their Family Members. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 650-655.	1.2	19
33	Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from <scp>REGARD</scp>, <scp>RAINBOW</scp>, and <scp>RAINFALL</scp> Phase <scp>III</scp> Studies. <i>Oncologist</i> , 2021, 26, e1538-e1547.	3.7	19
34	Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1418-1425.	7.3	19
35	What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 676-681.	4.9	18
36	Novel investigational biologics for the treatment of cancer cachexia. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1113-1120.	3.1	17

#	ARTICLE	IF	CITATIONS
37	Adherence to Measuring What Matters Measures Using Point-of-Care Data Collection Across Diverse Clinical Settings. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 497-503.	1.2	17
38	Evidence-based Palliative Care Approaches to Non-pain Physical Symptom Management in Cancer Patients. <i>Seminars in Oncology Nursing</i> , 2018, 34, 227-240.	1.5	17
39	Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 1: Physical symptoms. <i>The Journal of Supportive Oncology</i> , 2010, 8, 100-16.	2.3	16
40	Assessing Emotional Suffering in Palliative Care: Use of a Structured Note Template to Improve Documentation. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 1-7.	1.2	15
41	Adherence to Measuring What Matters Items When Caring for Patients With Hematologic Malignancies Versus Solid Tumors. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 775-782.	1.2	15
42	Pain Syndromes and Management in Adult Hematopoietic Stem Cell Transplantation. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 551-567.	2.2	15
43	Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 2: psychosocial concerns. <i>The Journal of Supportive Oncology</i> , 2010, 8, 179-83.	2.3	15
44	Percentile-based averaging and skeletal muscle gauge improve body composition analysis: validation at multiple vertebral levels. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 190-202.	7.3	13
45	In Chemotherapy for Lung Cancer, Sometimes Less is More. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 232-235.	4.9	12
46	Variable Patterns of Continuous Morphine Infusions at End of Life. <i>Journal of Palliative Medicine</i> , 2015, 18, 786-789.	1.1	12
47	Palliative Radiation Before Hospice: The Long and the Short of It. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 1070-1079.	1.2	11
48	Enhancing legacy in palliative care: study protocol for a randomized controlled trial of Dignity Therapy focused on positive outcomes. <i>BMC Palliative Care</i> , 2015, 14, 44.	1.8	11
49	Concordance Between Veterans' Self-Report and Documentation of Surrogate Decision Makers: Implications for Quality Measurement. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 1-4.	1.2	11
50	Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. <i>Oncologist</i> , 2021, 26, 325-331.	3.7	11
51	Addressing Hereditary Cancer Risk at the End of Life. <i>Journal of Oncology Practice</i> , 2017, 13, e851-e856.	2.5	10
52	Cost Savings Associated With Palliative Care Among Older Adults With Advanced Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 1250-1257.	1.4	10
53	Associations of Skeletal Muscle With Symptom Burden and Clinical Outcomes in Hospitalized Patients With Advanced Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 319-327.	4.9	10
54	Tailoring Palliative Care to the Changing Needs of People Facing Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 813-815.	1.6	9

#	ARTICLE	IF	CITATIONS
55	Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies. <i>Journal of Palliative Medicine</i> , 2018, 21, 694-699.	1.1	9
56	Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. <i>Oncologist</i> , 2021, 26, e963-e970.	3.7	9
57	Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1846-e1855.	2.9	9
58	Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital. <i>Supportive Care in Cancer</i> , 2013, 21, 2817-2824.	2.2	8
59	Olanzapine in the Treatment of Refractory Nausea and Vomiting: A Case Report and Review of the Literature. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2015, 29, 148-152.	0.8	8
60	Transfusion practices at end of life for hematopoietic stem cell transplant patients. <i>Supportive Care in Cancer</i> , 2018, 26, 1927-1931.	2.2	8
61	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Hematologic Malignancies. <i>Journal of Palliative Medicine</i> , 2019, 22, 1449-1454.	1.1	8
62	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 6343-6353.	7.0	8
63	Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. <i>Future Oncology</i> , 2021, 17, 3027-3035.	2.4	8
64	Hospitalization costs for nausea and vomiting: A savings opportunity.. <i>Journal of Clinical Oncology</i> , 2017, 35, 155-155.	1.6	8
65	Cancer cachexia: the elephant in the room?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 3-4.	7.3	8
66	Leveraging the Potential Synergy Between Patient-Reported Outcomes and Body Composition Analysis in Patients with Cancer. <i>Oncologist</i> , 2020, 25, 271-273.	3.7	7
67	Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	4.1	7
68	Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 56-64.	0.1	7
69	The Implementation of Measuring What Matters in Research and Practice: Series Commentary. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 772-775.	1.2	6
70	More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 1793-1797.	2.2	6
71	Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience. <i>Cancer Medicine</i> , 2021, 10, 7152-7161.	2.8	6
72	Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e1587-e1593.	2.9	6

#	ARTICLE	IF	CITATIONS
73	Lack of Documentation of Evidence-Based Prognostication in Cancer Patients by Inpatient Palliative Care Consultants. <i>Journal of Palliative Medicine</i> , 2015, 18, 382-385.	1.1	5
74	Patient-Controlled Analgesia for Cancer-Related Pain: Clinical Predictors of Patient Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 595-600.	4.9	5
75	Opioid and Benzodiazepine Relative Use in Breast Cancer Patients Before, During, and After Curative Chemotherapy. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2018, 32, 27-29.	0.8	5
76	Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. <i>Future Oncology</i> , 2020, 16, 1863-1872.	2.4	5
77	Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103143.	4.4	5
78	Caregiver Reported Quality of End-of-Life Care of Adolescent and Young Adult Decedents With Cancer. <i>Journal of Palliative Care</i> , 2022, 37, 87-92.	1.0	5
79	FIT: Functional and imaging testing for patients with metastatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 208-208.	1.6	5
80	Rapidly progressive subcutaneous metastases from gallbladder cancer: insight into a rare presentation in gastrointestinal malignancies. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, E58-64.	1.4	5
81	Exploring the Definition of an Informed Health Care Proxy. <i>Journal of Palliative Medicine</i> , 2016, 19, 250-251.	1.1	4
82	A Pilot Study of Neoadjuvant FOLFIRINOX followed by Chemoradiation for Gastric and Gastroesophageal Cancer: Preliminary Results and Prognostic Implications of ctDNA. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S85-S86.	0.8	4
83	Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 242-252.	1.5	4
84	Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia. <i>Blood</i> , 2015, 126, 537-537.	1.4	4
85	Advance care planning and palliative care consultation for stem cell transplant patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 113-113.	1.6	4
86	Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen.. <i>Journal of Clinical Oncology</i> , 2017, 35, 120-120.	1.6	4
87	Inpatient hospitalization costs associated with nausea and vomiting among patients with cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 112-112.	1.6	4
88	A pilot study of neoadjuvant FOLFIRINOX followed by chemoradiation for gastric and gastroesophageal cancer: Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4057-4057.	1.6	4
89	Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for prevention of emesis following highly emetogenic chemotherapy (HEC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 194-194.	1.6	4
90	Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24133-e24133.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Bereaved Caregivers Perspectives of Negative Communication Experiences Near the End of Life for Adolescents and Young Adults with Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 498-505.	1.3	4
92	The Cambia Sojourns Scholars Leadership Program: Projects and Reflections on Leadership in Palliative Care. <i>Journal of Palliative Medicine</i> , 2019, 22, 823-829.	1.1	3
93	Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care. <i>JCO Oncology Practice</i> , 2020, 16, e132-e138.	2.9	3
94	Exploring the Expanded Role of Pharmacists in Advance Care Planning. <i>JCO Oncology Practice</i> , 2021, 17, 102-106.	2.9	3
95	A single-center, retrospective chart review evaluating outpatient code status documentation in the EPIC electronic medical record for patients with advanced solid tumor cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 242-242.	1.6	3
96	Economic impact of palliative care among elderly cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 91-91.	1.6	3
97	Managing Malignant Bowel Obstruction: Moving Beyond Drip and Suck. <i>Journal of Oncology Practice</i> , 2017, 13, 437-438.	2.5	2
98	PARP-ness in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, iv117.	1.2	2
99	Reply to O. Huillard et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 3819-3819.	1.6	2
100	FIT: Functional and imaging testing for patients with metastatic cancer. <i>Supportive Care in Cancer</i> , 2021, 29, 2771-2775.	2.2	2
101	The Impact of Early Referrals to Dietitians for Patients With Esophagogastric Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 235-238.	4.9	2
102	Healthcare utilization and costs associated with cancer-related diarrhea.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18623-e18623.	1.6	2
103	Supportive oncology care at home intervention for patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6558-6558.	1.6	2
104	1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer. <i>Annals of Oncology</i> , 2021, 32, S1185.	1.2	2
105	Supportive oncology care at home intervention for patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 155-155.	1.6	2
106	Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 119-126.	0.9	2
107	Inclusion criteria for cancer cachexia clinical trials: CT-defined skeletal muscle loss versus body weight loss.. <i>Journal of Clinical Oncology</i> , 2015, 33, 67-67.	1.6	2
108	Efficacy of an intravenous formulation of NEPA, a fixed combination of fosnetupitant and palonosetron, compared with oral NEPA studies in the prevention of chemotherapy-induced nausea and vomiting (CINV): An analysis of 1026 patient experiences.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22177-e22177.	1.6	2

#	ARTICLE	IF	CITATIONS
109	What the HEC? Physician variation and attainable compliance targets in antiemetic prophylaxis.. Journal of Clinical Oncology, 2018, 36, 74-74.	1.6	2
110	Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC ≥ 4 .. Journal of Clinical Oncology, 2019, 37, 11595-11595.	1.6	2
111	BPI19-019: Avoidable Acute Care Use Associated With Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, BPI19-019.	4.9	2
112	CACHEXIO: Evaluation of body composition changes and immunotherapy in patients with metastatic cancer.. Journal of Clinical Oncology, 2018, 36, 209-209.	1.6	2
113	The impact of emergency general surgery on end-of-life care among older patients with metastatic cancer.. Journal of Clinical Oncology, 2018, 36, 56-56.	1.6	2
114	Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2019, 37, 3563-3563.	1.6	2
115	Acute care and hydration due to chemotherapy-induced nausea and vomiting (CINV) among patients receiving NEPA prophylaxis for anthracycline + cyclophosphamide (AC).. Journal of Clinical Oncology, 2019, 37, 112-112.	1.6	2
116	Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience.. Journal of Clinical Oncology, 2020, 38, 154-154.	1.6	2
117	Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers. Annals of Oncology, 2019, 30, iv112.	1.2	1
118	Revisiting <i>MET</i> : Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, <i>MET</i> -Amplified Esophagogastric Cancers. Oncologist, 2020, 25, e1691-e1700.	3.7	1
119	Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy.. Journal of Clinical Oncology, 2021, 39, e15611-e15611.	1.6	1
120	Important news on nutritional support in cancer patients “ but some EFFORT is still ahead. Annals of Oncology, 2021, 32, 954-956.	1.2	1
121	Early outcome of a phase I study of interrupted pulse dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 473-473.	1.6	1
122	Analysis of weight loss as a prognostic factor in patients (pts) with advanced gastric cancer from REGARD, RAINBOW and RAINFALL phase III studies.. Journal of Clinical Oncology, 2020, 38, 348-348.	1.6	1
123	Noninvasive comprehensive genomic profiling from plasma ctDNA in pancreatic cancer patients.. Journal of Clinical Oncology, 2020, 38, 753-753.	1.6	1
124	inSIRT trial: Single-center phase II study of yttrium-90 radioactive resin microspheres in the treatment of liver-predominant metastatic colorectal adenocarcinoma after failure of first-line combination chemotherapy.. Journal of Clinical Oncology, 2012, 30, e14079-e14079.	1.6	1
125	A single center, retrospective analysis evaluating aberrant drug behavior stratification utilizing the opioid risk tool in patients with cancer.. Journal of Clinical Oncology, 2013, 31, 167-167.	1.6	1
126	Molecular tumor profiling ordering trends in cancer patients.. Journal of Clinical Oncology, 2016, 34, 165-165.	1.6	1

#	ARTICLE	IF	CITATIONS
127	Palliative care and health care utilization at the end of life.. Journal of Clinical Oncology, 2016, 34, 152-152.	1.6	1
128	Blood transfusions at end of life for stem cell transplant patients.. Journal of Clinical Oncology, 2016, 34, 115-115.	1.6	1
129	Chemotherapy-Induced Nausea and Vomiting (CINV) in Hematologic Malignancy Patients Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC). Blood, 2016, 128, 2410-2410.	1.4	1
130	Advance care planning in Hispanic/Latino and non-Hispanic white patients with cancer.. Journal of Clinical Oncology, 2017, 35, 10-10.	1.6	1
131	More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer.. Journal of Clinical Oncology, 2018, 36, 211-211.	1.6	1
132	Abstract P5-14-07: Avoidable acute care involving chemotherapy-induced nausea and vomiting (CINV) among patients with breast cancer receiving anthracycline + cyclophosphamide (AC) with NEPA prophylaxis relative to other antiemetics: An external control arm analysis. , 2020, , .		1
133	Preliminary analysis of total neoadjuvant therapy for patients with locally advanced gastric (G) and gastroesophageal (GE) adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, 393-393.	1.6	1
134	Missing Voices: Lessons Learned from Nonparticipating Caregivers in Palliative Care Research. Journal of Palliative Medicine, 2022, 25, 455-460.	1.1	1
135	Associations of sarcopenia with hematologic toxicity, treatment intensity, and healthcare utilization in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 84-84.	1.6	1
136	Leading from the Heart. Journal of Pain and Symptom Management, 2022, 63, e645-e646.	1.2	1
137	Darkness is No More. Journal of Palliative Medicine, 2009, 12, 389-390.	1.1	0
138	Redefining the Role of Paternalism in Palliative Medicine (SA511). Journal of Pain and Symptom Management, 2013, 45, 400.	1.2	0
139	Octreotide Prescribing Patterns in the Palliation of Symptomatic Inoperable Malignant Bowel Obstruction Patients at a Single US Academic Hospital (FR416-B). Journal of Pain and Symptom Management, 2013, 45, 373-374.	1.2	0
140	Clinical Supervision: An Antidote to Personal and Team Compassion Fatigue (SA504). Journal of Pain and Symptom Management, 2014, 47, 447-448.	1.2	0
141	1590 Patient-related factors in determining the emetic risk potential for patients undergoing chemotherapy: An evaluation of predictive models for the development of a risk assessment tool. European Journal of Cancer, 2015, 51, S234.	2.8	0
142	The Polypharmacy Police Versus the Patient Advocate: An Evidence-Based, Patient-Tailored Approach to Medication Simplification Strategies for the Palliative Care Patient (SA517). Journal of Pain and Symptom Management, 2015, 49, 395-396.	1.2	0
143	Titrate to Death? Prescribing Patterns of Continuous Morphine Infusions at End of Life (S758). Journal of Pain and Symptom Management, 2015, 49, 437.	1.2	0
144	The Default Dilemma: Code Status Regardless of Medical Context. Journal of Palliative Medicine, 2016, 19, 1134-1134.	1.1	0

#	ARTICLE	IF	CITATIONS
145	Patient-Controlled Analgesia for Cancer-Related Pain: Clinical Predictors of Patient Outcomes (S785). Journal of Pain and Symptom Management, 2016, 51, 454-455.	1.2	0
146	Evaluation of Cost of Hospitalizations Related to Nausea and Vomiting Among Cancer Patients. Value in Health, 2018, 21, S27.	0.3	0
147	A National Survey Study of Transplant Physicians' Attitudes About Palliative Care. Biology of Blood and Marrow Transplantation, 2018, 24, S59-S60.	2.0	0
148	Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study. Annals of Oncology, 2019, 30, iv111.	1.2	0
149	What's the Deal with Blood Cancers? Navigating a New Frontier in Palliative Cancer Care (TH313). Journal of Pain and Symptom Management, 2019, 57, 371.	1.2	0
150	Total Neoadjuvant Therapy versus Neoadjuvant Chemoradiotherapy in the Management of Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, e602-e603.	0.8	0
151	Neoadjuvant versus Postoperative Chemoradiotherapy in Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, e632.	0.8	0
152	The impact of cancer-related diarrhea on changes in cancer therapy patterns.. Journal of Clinical Oncology, 2021, 39, 12111-12111.	1.6	0
153	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2021, 39, 6560-6560.	1.6	0
154	Characterizing unplanned resource utilization associated with cancer-related diarrhea.. Journal of Clinical Oncology, 2021, 39, e18625-e18625.	1.6	0
155	Assessing duration of breakthrough chemotherapy-induced nausea and vomiting (CINV): A pooled study analysis of NEPA versus aprepitant.. Journal of Clinical Oncology, 2021, 39, 12091-12091.	1.6	0
156	ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. Annals of Surgical Oncology, 2021, 28, 690-691.	1.5	0
157	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2021, 39, 154-154.	1.6	0
158	Early outcome of a phase II study of yttrium-90 radioactive resin microspheres in the treatment of colorectal adenocarcinoma metastatic to the liver after failure of first-line combination chemotherapy (inSIRT Trial).. Journal of Clinical Oncology, 2011, 29, 626-626.	1.6	0
159	inSIRT trial: Single-center phase II study of yttrium-90 radioactive resin microspheres in the treatment of liver-predominant metastatic colorectal adenocarcinoma after failure of first-line combination chemotherapy.. Journal of Clinical Oncology, 2012, 30, 685-685.	1.6	0
160	Molecular predictors of treatment response in colon and gastric cancer.. Journal of Clinical Oncology, 2012, 30, 619-619.	1.6	0
161	Abstract 3692: Single center phase II study of yttrium-90 radioactive resin microspheres in the treatment of liver predominant metastatic colorectal adenocarcinoma after failure of 1st-line combination chemotherapy. , 2012, , .		0
162	Molecular predictors of treatment response in colon and gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14069-e14069.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Re-evaluating the inpatient use of routine diphenhydramine transfusion premedication practices.. Journal of Clinical Oncology, 2013, 31, 164-164.	1.6	0
164	Single-center, prospective pilot study to evaluate advance care planning implementing the 3 Questions and 3 Elements to identify an informed health care proxy in an outpatient oncology palliative care clinic.. Journal of Clinical Oncology, 2014, 32, TPS9655-TPS9655.	1.6	0
165	Predictors of progression in patients with high-grade appendiceal or colorectal adenocarcinoma after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.. Journal of Clinical Oncology, 2014, 32, e14573-e14573.	1.6	0
166	Patterns of palliative care consultation among elderly cancer patients.. Journal of Clinical Oncology, 2015, 33, e17557-e17557.	1.6	0
167	Code status documentation in the electronic medical record for patients with stage IV pancreatic cancer.. Journal of Clinical Oncology, 2016, 34, 125-125.	1.6	0
168	Administration of the ASCO Pain Survey to identify patient education deficiencies in patients with cancer.. Journal of Clinical Oncology, 2017, 35, 68-68.	1.6	0
169	Palliative care pharmacists as advocates to conduct advance care planning.. Journal of Clinical Oncology, 2017, 35, 73-73.	1.6	0
170	Next-generation sequencing ordering trends in the cancer trajectory.. Journal of Clinical Oncology, 2017, 35, 10104-10104.	1.6	0
171	Abstract P4-16-05: Avoidable acute care use associated with nausea and emesis among patients receiving AC, carboplatin, or cisplatin for breast cancer. , 2019, , .		0
172	Potentially avoidable acute care use among patients receiving oxaliplatin.. Journal of Clinical Oncology, 2019, 37, 651-651.	1.6	0
173	Ondansetron versus palonosetron as a marker of non-adherence to antiemetic prophylaxis guidelines in highly emetogenic chemotherapy.. Journal of Clinical Oncology, 2019, 37, e23108-e23108.	1.6	0
174	Abstract LB-257: Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers. , 2019, , .		0
175	The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2020, 38, 833-833.	1.6	0
176	Relationships among skeletal muscle, symptom burden, health care use, and survival in hospitalized patients with advanced cancer.. Journal of Clinical Oncology, 2020, 38, 7006-7006.	1.6	0
177	Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer.. Journal of Clinical Oncology, 2020, 38, 186-186.	1.6	0
178	A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, 564-564.	1.6	0
179	Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2022, 40, 6570-6570.	1.6	0